NATx Core News & Resources

  • NATx Operations Manager Dr. Katelyn Lacy presents at the 10th Annual RNA Symposium 
  • Core staff “graduate” from Agilent University – Drs. Hala Abou Assi and Michaela Everly completed the four-day “Agilent 6200/6500 Series LC/TOF/Q-TOF Techniques and Operation for Large Molecules” training course at Agilent Technologies in Lexington, MA, where they learned valuable hands-on experience and practical insights into LC/MS for large molecules and oligonucleotide analysis. They are looking forward to applying what they learned at the NATx Core at the University of Michigan! 

NATx in the News

Two scientists work in the NATx core

$3.9 million NIH grant to fuel U-M effort to develop first targeted therapy for fatal childhood brain disorder

The University of Michigan has received a $3.9 million award from the National Institutes of Health's Ultra-rare Gene-based Therapy (URGenT) Program to develop a novel antisense oligonucleotide (ASO) medicine for CLN3 Batten disease, a rare, fatal genetic disorder.

Researchers tour the new NATx core space while a staff member explains equipment

New research core removes barriers to RNA-based research and drug discovery efforts at U-M

The Nucleic Acids Therapeutics (NATx) Core brings novel nucleic acid–based research functions to the university, one of the first full-service centers of its type in an academic setting.